Continuous infusion of recombinant factor VIIa (NovoSeven) in the treatment of a patient with type III von Willebrand's disease and alloantibodies against von Willebrand factor.
Grossmann
R E
RE
Geisen
U
U
Schwender
S
S
Keller
F
F
D000707:Anaphylaxis / Q000209:etiology; D004844:Epistaxis / Q000209:etiology / Q000628:therapy; D015942:Factor VIIa / Q000008:administration & dosage* / Q000627:therapeutic use; D006406:Hematoma / Q000209:etiology / Q000628:therapy; D006801:Humans; D007262:Infusions, Intravenous; D007518:Isoantibodies / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D012008:Recurrence; D014842:von Willebrand Diseases / Q000145:classification / Q000150:complications / Q000276:immunology / Q000628:therapy*; D014841:von Willebrand Factor / Q000276:immunology*
D007518:Isoantibodies; D011993:Recombinant Fusion Proteins; D014841:von Willebrand Factor; D015942:Factor VIIa